ArticleInfectious diseases of poverty2019
Elimination of onchocerciasis in Africa by 2025: the need for a broad perspective.
Article in Infectious diseases of poverty, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The risk of onchocerciasis infection by human population movements between high and low transmission settings in Ghana.PLoS neglected tropical diseases · 2026Article
- Effects of Five Years of Treatment of Onchocerciasis with Ivermectin under Community Guidelines in Resurgent Areas of Burkina Faso: A before-and-after Analysis.Tropical medicine and infectious disease · 2024Article
- Ecological assessment of Black Fly (Simuliumdamnosum, Sensulato) breeding sites in two tributaries of Ogun river, Ogun state, Nigeria.Environmental monitoring and assessment · 2022Article
- Knowledge, Attitude, and Preventive Practice Related to Onchocerciasis and Associated Factors among Resource-Limited Selamogo Woreda Residents, South West Ethiopia, 2021.Journal of tropical medicine · 2022Article
- Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis.PLoS neglected tropical diseases · 2021Article
- Entomological Assessment ofPathogens (Basel, Switzerland) · 2020Article
- The Role of the Maridi Dam in Causing an Onchocerciasis-Associated Epilepsy Epidemic in Maridi, South Sudan: An Epidemiological, Sociological, and Entomological Study.Pathogens (Basel, Switzerland) · 2020Article
- Elimination of onchocerciasis in Africa by 2025: an ambitious target requires ambitious interventions.Infectious diseases of poverty · 2019Article
- The need for evidence-based strategies and tools for onchocerciasis elimination in Africa.Infectious diseases of poverty · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn response to the recent publication "Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes" by Dadzie et al., it is important to clarify and highlight the positive and unequivocal research and operational contributions from the American experience towards the worldwide elimination of human onchocerciasis (river blindness). MAIN TEXT: The strategies of twice or more rounds of mass drug administration (MDA) of ivermectin per year, as well as the use of OV-16 serology have allowed four American countries to be verified by World Health Organization to have eliminated transmission of Onchocerca volvulus, the etiological agent. These advances were also implemented in Sudan and Uganda; currently, both are the only African countries where ivermectin MDA was safely stopped in several transmission zones.
conclusionsProgrammatic treatment and evaluation approaches, pioneered in the Americas, are the most efficient among the existing tools for elimination, and their broader use could catalyze the successful elimination of this disease in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.